By Sriparna Roy
(Reuters) – Value will increase on 5 of the ten medicine that contributed probably the most to rising U.S. medical spending in 2023 weren’t supported by medical proof and resulted in an $815 million enhance in prices of {dollars}, an influential drug pricing watchdog mentioned Thursday.
The Institute for Scientific and Financial Evaluate (ICER) mentioned half of the medicine evaluated had value will increase primarily based on new proof of extra advantages or diminished dangers, whereas the opposite half lacked such proof.
Johnson & Johnson’s (NYSE:) most cancers drug Darzalex was on the checklist of value will increase not supported by medical proof for the second time this 12 months. A 7.6% enhance within the remedy’s checklist value added about $190 million to U.S. spending, the report discovered.
ICER’s methodology represents the angle of insurance coverage firms, not sufferers, a Johnson & Johnson spokesperson mentioned.
The methodology is deeply flawed and omits key data, together with a brand new FDA approval and a number of research experiences, the spokesperson added.
Biktarvy, the anti-HIV drug from Gilead (NASDAQ:), Novartis (SIX:)’ coronary heart drug Entresto, Exelixis (NASDAQ:)’ most cancers remedy Cabometyx and Pfizer (NYSE:), rheumatoid arthritis drug Xeljanz, are the 4 different medicine that contributed to the rise in spending with out being supported by knowledge.
Biktarvy contributed greater than the opposite 4 on the checklist, mentioned Foluso Agboola, ICER vp of analysis.
The report ignored proof on Biktarvy, together with knowledge that led to 2 FDA label updates and two medical guideline updates due to its significance to medical apply, mentioned a Gilead spokesperson.
“We proceed to see value will increase effectively above the speed of inflation for most of the costliest medicine,” Agboola added.
Final 12 months, eight of the ten costliest medicine noticed substantial value will increase, accounting for $1.27 billion in extra prices, in keeping with the American Value Analysis Society.
Merck (NS:)’s Keytruda was among the many ten costliest medicine, however ICER mentioned the 4.1% enhance within the remedy’s checklist value was supported by medical proof.
Regardless that the medicine had new medical proof, the report didn’t try to find out whether or not the value will increase have been absolutely justified by assembly a benchmark value by way of well being advantages that may very well be decided by an evaluation formal cost-effectiveness.
#Unjustified #value #hikes #added #million #U.S #pharmaceutical #spending #Reuters , #Gossip247
,
